How does capivasertib treat breast cancer?

What is capivasertib, and how does it work in breast cancer treatment?

Capivasertib, also known as lipasertib, is a small molecule inhibitor that targets the AKT signaling pathway [1]. This pathway plays a crucial role in cell survival and proliferation, particularly in cancer cells. By inhibiting AKT, capivasertib aims to slow down or halt the growth of cancer cells.

How is capivasertib administered, and what are its potential benefits?

Capivasertib is typically administered orally. Researchers have been exploring its potential in the treatment of various cancers, including breast cancer, particularly in patients with hormone receptor-positive, HER2-negative disease [2]. The drug has shown promise in reducing tumor growth and improving overall survival.

What are the results of clinical trials involving capivasertib and breast cancer?

Clinical trials have investigated the efficacy and safety of capivasertib in combination with standard therapies for breast cancer. A 2020 phase 3 trial demonstrated that capivasertib plus fulvestrant extended progression-free survival compared to fulvestrant alone in patients with hormone receptor-positive, HER2-negative metastatic breast cancer [3]. More studies are needed to confirm these findings and explore the potential of capivasertib in various breast cancer subtypes.

When and where is capivasertib approved for use in breast cancer?

Capivasertib has been approved in certain regions for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer, but regulatory approvals may vary by country. Consult the relevant health agency's website for the most up-to-date information.

What side effects are patients taking capivasertib concerned about?

Common side effects associated with capivasertib include diarrhea, nausea, rash, and increased liver enzymes. More severe side effects can occur, and patients should discuss any concerns with their healthcare provider [4].

What are the patent and exclusivity landscape for capivasertib?

The patent landscape for capivasertib is evolving, and exclusivity periods can vary by region. Check the patent status of capivasertib through trusted resources like DrugPatentWatch.com [5].

Sources:
[1] https://www.drugbank.ca/drugs/DB14923
[2] https://www.clinicaltrials.gov/ct2/show/NCT02099726
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2021425
[4] https://www.drugwatch.com/capivasertib-side-effects/
[5] https://www.drugpatentreview.com/companies/aurinia- pharmaceuticals (AUR)

Note: This answer aims to provide a clear and concise overview of capivasertib's mechanism of action, clinical trials, and regulatory status in breast cancer treatment. For the most up-to-date information, consult reputable sources and healthcare professionals.